Circulating levels of frizzled-related protein (FRZB) are increased in patients with early rheumatoid arthritis and decrease in response to disease-modifying antirheumatic drugs

Annals of the Rheumatic Diseases

Volumn 69, Issue 9, 2010, Pages 1733-1734

  Corallini, Federica ^a   Secchiero, Paola ^a   Castellino, Gabriella ^a   Montecucco, Maurizio ^b   Trotta, Francesco ^a   Zauli, Giorgio ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CITRULLINATED PROTEIN ANTIBODY; CITRULLINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FRIZZLED PROTEIN; PROTEIN ANTIBODY; PROTEIN FRZB; UNCLASSIFIED DRUG;

DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEROLOGY; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; GLYCOPROTEINS; HUMANS;

EID: 77956043014     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.125732     Document Type: Letter

References (5)

1. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 2009;13:485-96.
2. Loughlin J, Dowling B, Chapman K, et al. Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. Proc Natl Acad Sci USA 2004;101:9757-62.
3. Lane NE, Lian K, Nevitt MC, et al. Frizzled-related protein variants are risk factors for hip osteoarthritis. Arthritis Rheum 2006;54:1246-54.
4. Lories RJ, Peeters J, Bakker A, et al. Articular cartilage and biomechanical properties of the long bones in Frzb-knockout mice. Arthritis Rheum 2007;56:4095-103. (Pubitemid 350262337)
5. Pasero G, Priolo F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996;39:1006-15.